Annual Financial Report

2 October 2012

ANTISOMA PLC

AUDITED RESULTS FOR THE YEAR ENDED 30 JUNE 2012

Antisoma plc ("Antisoma" or the "Company) announces its audited financial results for the year ended 30 June 2012.

Highlights:

·; Net assets as at 30 June 2012 of £12.91 million (2011: £12.53 million); including cash and deposit balances of £12.91 million (2011: £12.31 million)

·; Profit after tax of £0.38 million (2011: loss of £69.32 million)

·; Administrative costs for the year, inclusive of the cost of moving to AIM, reduced to £0.18 million (2011: £4.65 million)

·; Move to AIM Market as an Investing Company completed in January 2012

·; First investment made; £1m stake in a profitable care sector services business

Michael Pappas, Chairman, said:

"Antisoma benefits from a solid balance sheet and strong cash position, together with a low cost base. This places the Company in a good position to exploit opportunities as they emerge in the current volatile economic environment. The intention is to maintain a highly selective investment approach with a view to building considerable value for shareholders going forward."

A full copy of the Company's Annual Report and Accounts for the year ended 30 June 2012, together with the Notice of Annual General Meeting, will shortly be posted to shareholders and is available on the Company's website at www.antisoma.com within the Investor Centre section.

The Company's Annual General Meeting will be held on 25 October 2012 at 10.30 a.m. at the offices of CMS Cameron McKenna LLP, Mitre House, 160 Aldersgate Street, London EC1A 4DD.

 Enquiries:

Chairman's Statement

Overview

On 7 December 2011, the Company's shareholders approved proposals to cancel Antisoma's listing on the Official List and to seek admission to trading of its shares on AIM. The Company was subsequently admitted to AIM on 11 January 2012 as an Investing Company.

This process followed the discontinuation of key clinical trials in early 2011 and the decision to cease all of the Group's clinical development and biotechnology programmes and reduce central overheads to a minimum in order to preserve cash resources. The continuing Board then reviewed a range of alternative strategies and opportunities in order to generate value for shareholders. The outcome was an agreed strategy to identify and invest in a number of businesses with significant potential for value creation rather than commit the whole of Antisoma's cash resource to a single investment. It also became clear to the Board that the AIM market would be more appropriate for the trading of the Company's shares given its current strategy and size. In particular, the move to AIM means that corporate transactions and investments can now be executed more quickly and cost effectively.

Since the Company's admission to AIM, the Board has adopted a highly selective investment approach in these times of global economic uncertainty for which downside risks appear to loom large and theEuropean sovereign debt crisis remains a major concern, along with the effects of austerity measures on economic growth. Consequently, whilst the Board has identified and reviewed a number of potential opportunities to date, including some introduced by the Company's largest shareholder (which is expected to be a major source of potential investment opportunities going forward), we have only made one relatively small investment of £1.0 million under the new investing strategy. That investment is in a profitable AIM listed care sector support services business with a solid dividend yield and a good growth record.

Antisoma had cash and short term deposit balances of £12.91 million at 30 June 2012 which places it in a strong position to take advantage of further investment opportunities that arise. The Board intends the Company typically to be an active investor and to assist in the strategic development and growth of any significant acquisitions and/or investments it makes and which may be either quoted or unquoted and may range from a minority position to 100 per cent. ownership. A particular consideration will be to identify businesses which, in the opinion of the Board, are under-performing and present opportunities for high value creation.

Financial highlights

The Group reported a profit after tax of £0.38 million for year to 30 June 2012 (2011: loss of £69.32 million) with administrative costs reduced to £0.17 million inclusive of the cost of moving to AIM (2011: £4.65 million). At 30 June 2012 the Group had net assets of £12.91 million (2011: £12.53 million) and cash and short term deposit balances of £12.91 million (2011: £12.31 million).

Board and management changes

Grahame Cook and Michael Lewis did not seek re-appointment at the last Annual General Meeting ("AGM") on 7 December 2011 following the agreed change of strategy to an investing company and Ross Hollyman was appointed as an additional Non-Executive Director at the AGM. Now that the Company has completed its move on to the AIM market and has prepared its first Annual Report as an investing company, Dale Boden and I have announced we will not be seeking re-appointment at the next AGM on 25 October 2012 due, in particular, to our geographical remoteness from the operations of the Company. It is proposed that Michael Bretherton will, subject to his re-appointment at the AGM, succeed me as Chairman. Michael is also a director of ORA Capital, the Company's largest shareholder. The Board would like to take this opportunity to thank all of the above retiring and retired directors for their contributions to the Company, and in particular their assistance in transitioning the Company from its legacy biotechnology operations into an investing company on AIM. In addition, it is proposed that Jonathan Morley-Kirk be appointed as an additional Independent Non-Executive Director at the AGM on 25 October 2012. A summary of his biographical details are set out in note 18 of the Notice of AGM and in the separate RNS announcement released this morning.  

Outlook

Whilst European sovereign debt problems remain the major downside risk for Europe and the global economy, Antisoma benefits from a solid balance sheet and strong cash position, together with a low cost base. This places the Company in a good position to exploit opportunities as they emerge in the current volatile economic environment. We will therefore, continue to maintain a highly selective investment approach with a view to building considerable value for shareholders going forward.

Michael Pappas

Non-Executive Chairman

1 October2012

Consolidated income statement for the year ended 30 June 2012

Consolidated statement of changes in equity as at 30 June 2012

Consolidated statement of financial position at 30 June 2012

Consolidated statement of cash flows for the year ended 30 June 2012